항독소 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 종별, 유형, 지역별 및 경쟁(2021-2031년)

The Global Anti-Venom Market is projected to expand from USD 1.38 Billion in 2025 to USD 2.07 Billion by 2031, reflecting a CAGR of 6.98%. Anti-venom consists of biological preparations containing antibodies obtained from the plasma of immunized animals, designed to neutralize toxins from bites or stings. Growth is primarily driven by the increasing global prevalence of snake envenoming and strengthened government efforts to address this neglected tropical disease, creating a critical need for reliable therapeutics to reduce mortality rates. World Health Organization data from 2024 indicates that between 1.8 and 2.7 million snakebite poisoning cases occur annually, leading to approximately 81,410 to 137,880 deaths.

Despite this urgent need, the market faces significant hurdles due to high manufacturing costs and the logistical complexities of maintaining cold chains in isolated areas. These factors increase the final cost of treatment, limiting availability in low-income regions where the need is most acute. Consequently, the financial inability of vulnerable populations to access these essential medicines remains a major barrier that threatens to hinder the broader expansion of the global market.

Market Driver

Rising research and development investments in novel and recombinant therapeutics are transforming the global anti-venom landscape by overcoming the limitations of traditional plasma-based products. Manufacturers and research institutions are increasingly focusing on small molecule inhibitors and oral treatments that provide better stability and easier administration in resource-poor settings. This innovation is supported by significant funding to modernize snakebite care; for example, Vrije Universiteit Amsterdam announced in October 2024 that a consortium secured €5 million to advance clinical trials for oral snakebite drugs. These investments hasten the development of next-generation therapeutics, enhancing the market's ability to supply effective solutions to remote regions.

Government initiatives and funding for neglected tropical diseases act as vital market stabilizers by ensuring consistent demand and distribution. Public sector entities are formalizing partnerships with manufacturers to maintain antivenom stockpiles for at-risk populations, thereby reducing production-related commercial risks. Illustrating this, the Australian Government extended a program in June 2024 to donate up to 600 antivenom vials annually to Papua New Guinea, strengthening regional health security. This engagement highlights the sector's commercial potential, further evidenced by Mankind Pharma's 2024 agreement to acquire Bharat Serums and Vaccines for approximately INR 13,630 crore, emphasizing the value placed on established antivenom capabilities.

Market Challenge

A primary obstacle to the Global Anti-Venom Market's growth is the high cost of manufacturing combined with strict cold chain requirements, which severely restricts access in low-income, high-need regions. Producing antivenom requires a resource-intensive biological process involving animal immunization, resulting in high unit costs. Additionally, the rigorous temperature controls necessary to preserve these products during transport create logistical bottlenecks in remote areas where snakebites are most common. These economic and infrastructural barriers create a disconnect between urgent clinical needs and commercial realities, as populations with the highest incidence rates often lack the funds for unsubsidized treatments.

This gap limits addressable market revenue, as potential demand cannot be converted into sustainable financial growth without external support. Insufficient resources exacerbate the issue by stalling efforts to stabilize supply chains or subsidize costs. For instance, the World Health Organization noted in 2024 that the global strategy for snakebite prevention had secured less than 12% of its required operational budget. This significant funding shortfall highlights the severe financial constraints preventing the market from expanding into territories where its products are most critically needed, thereby capping overall industry progress.

Market Trends

Artificial intelligence is revolutionizing venom characterization and drug discovery by reducing reliance on traditional animal immunization to identify toxin-neutralizing molecules. Deep learning algorithms now enable the design of synthetic proteins that specifically target lethal venom components which often escape conventional antibodies. This technological advancement improves the speed and specificity of therapeutic development while offering a scalable alternative to plasma-derived products. For example, DTU Bioengineering reported in January 2025 that researchers utilized these tools to create proteins that achieved an 80 to 100% survival rate in mice against lethal three-finger toxins.

At the same time, the market is shifting toward broad-spectrum polyvalent antivenom formulations to address the clinical challenge of identifying specific snake species during emergencies. In many high-burden regions, healthcare providers lack diagnostic tools, making universal cocktails essential for mitigating mortality risks across diverse snake families. This trend simplifies inventory management for rural health centers and ensures immediate treatment viability. As evidence of this progress, a May 2025 report from Columbia University highlighted the development of an antibody cocktail capable of neutralizing neurotoxins from 19 deadly species, providing complete protection against 13 in preclinical models.

Key Market Players

• Pfizer Inc.
• Merck KGaA
• Incepta Pharmaceuticals Limited
• CSL Ltd.
• Bharat Serums and Vaccines Ltd
• Boston Scientific Corporation
• Haffkine Bio-Pharmaceutical Corporation Limited
• DEKA M.E.L.A. S.R.L
• MicroPharm
• Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Anti-Venom Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Venom Market, By Species

• Snake
• Scorpion
• Spiders
• Other

Anti-Venom Market, By Type

• Polyvalent Anti-venoms
• Monovalent Anti-venom
• Other

Anti-Venom Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Venom Market.

Available Customizations:

Global Anti-Venom Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Venom Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Species (Snake, Scorpion, Spiders, Other)
  • 5.2.2. By Type (Polyvalent Anti-venoms, Monovalent Anti-venom, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Anti-Venom Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Species
  • 6.2.2. By Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Venom Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Species
      • 6.3.1.2.2. By Type
  • 6.3.2. Canada Anti-Venom Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Species
      • 6.3.2.2.2. By Type
  • 6.3.3. Mexico Anti-Venom Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Species
      • 6.3.3.2.2. By Type

7. Europe Anti-Venom Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Species
  • 7.2.2. By Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Venom Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Species
      • 7.3.1.2.2. By Type
  • 7.3.2. France Anti-Venom Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Species
      • 7.3.2.2.2. By Type
  • 7.3.3. United Kingdom Anti-Venom Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Species
      • 7.3.3.2.2. By Type
  • 7.3.4. Italy Anti-Venom Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Species
      • 7.3.4.2.2. By Type
  • 7.3.5. Spain Anti-Venom Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Species
      • 7.3.5.2.2. By Type

8. Asia Pacific Anti-Venom Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Species
  • 8.2.2. By Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti-Venom Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Species
      • 8.3.1.2.2. By Type
  • 8.3.2. India Anti-Venom Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Species
      • 8.3.2.2.2. By Type
  • 8.3.3. Japan Anti-Venom Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Species
      • 8.3.3.2.2. By Type
  • 8.3.4. South Korea Anti-Venom Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Species
      • 8.3.4.2.2. By Type
  • 8.3.5. Australia Anti-Venom Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Species
      • 8.3.5.2.2. By Type

9. Middle East & Africa Anti-Venom Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Species
  • 9.2.2. By Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti-Venom Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Species
      • 9.3.1.2.2. By Type
  • 9.3.2. UAE Anti-Venom Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Species
      • 9.3.2.2.2. By Type
  • 9.3.3. South Africa Anti-Venom Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Species
      • 9.3.3.2.2. By Type

10. South America Anti-Venom Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Species
  • 10.2.2. By Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti-Venom Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Species
      • 10.3.1.2.2. By Type
  • 10.3.2. Colombia Anti-Venom Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Species
      • 10.3.2.2.2. By Type
  • 10.3.3. Argentina Anti-Venom Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Species
      • 10.3.3.2.2. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti-Venom Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Incepta Pharmaceuticals Limited
• 15.4. CSL Ltd.
• 15.5. Bharat Serums and Vaccines Ltd
• 15.6. Boston Scientific Corporation
• 15.7. Haffkine Bio-Pharmaceutical Corporation Limited
• 15.8. DEKA M.E.L.A. S.R.L
• 15.9. MicroPharm
• 15.10. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer